Vacuqx hydrate, poudre ,> = 98 %(HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

NBQX hydrate has been used: as a non-N-methyl-D-aspartate receptor (NMDA) 2-amino-3-hydroxy-5-methyl-4-isoxazol propionic acid (AMPA) receptor antagonist to monitor gonadotropin responsesα-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antagonist in monocytesAMPA and N-methyl-D-aspartate receptor (NMDA) antagonist in migrating interneurons expressing potassium-chloride cotransporter (shKCC2)

Biochem/physiol Actions

NBQX [2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo(F)quinoxaline], an anticonvulsant provides protection against white matter damage in spinal cord crush injury and also protects oligodendrocyte in experimental autoimmune encephalomyelitis (EAE). However, its role in preventing inflammation in EAE is not yet clear.

Neuroprotective AMPA/kainate glutamate receptor antagonist.

General description

NBQX [2,3-dihydroxy-6-nitro-7-sulphamoyl-benzo(F)quinoxaline] is a competitive antagonist, which shows high affinity to 2-amino-3-hydroxy-5-methyl-4-isoxazol propionic acid (AMPA) receptor than kainite receptor.

Packaging

5, 25 mg in glass bottle